Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.36 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023981 | 0.79 | CASP3 (0.33) | PLA2G10PLA2G5CASP3KDM4EALDH1A1 | |
| SCHEMBL6361822 | 0.75 | PLA2G10 (0.41) | PLA2G10PLA2G5ITGB3ITGA2BKDM4E | |
| SCHEMBL5025458 | 0.68 | MEN1 (0.43) | PLA2G10PLA2G5CASP3 | |
| SCHEMBL5029922 | 0.67 | PLA2G10 (0.31) | PLA2G10PLA2G5CASP3 | |
| SCHEMBL6283587 | 0.67 | LMNA (0.48) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL5030092 | 0.65 | MEN1 (0.45) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL17951050 | 0.65 | PLA2G10 (0.42) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL18204610 | 0.65 | PLA2G10 (0.42) | PLA2G10PLA2G5KDM4EALDH1A1 | |
| SCHEMBL5023979 | 0.65 | PLA2G10 (0.33) | PLA2G10PLA2G5 | |
| SCHEMBL7126798 | 0.65 | CHRM2 (0.34) | PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ABBOTT GMBH & CO. KG (DE) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221082-A1 | Ligands of Integrin Receptors | ITGB3, ITGAV, ITGA2B | PLA2G10 3666/4885PLA2G5 2330/4885ITGB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.